WO2000077167A3 - Herpes simplex virus amplicon vector targeting system and method of using same - Google Patents

Herpes simplex virus amplicon vector targeting system and method of using same Download PDF

Info

Publication number
WO2000077167A3
WO2000077167A3 PCT/US2000/016050 US0016050W WO0077167A3 WO 2000077167 A3 WO2000077167 A3 WO 2000077167A3 US 0016050 W US0016050 W US 0016050W WO 0077167 A3 WO0077167 A3 WO 0077167A3
Authority
WO
WIPO (PCT)
Prior art keywords
herpes simplex
simplex virus
same
targeting system
vector targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/016050
Other languages
French (fr)
Other versions
WO2000077167A2 (en
Inventor
Matthew A Spear
Xandra O Breakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
University of California Berkeley
University of California San Diego UCSD
Original Assignee
General Hospital Corp
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, University of California Berkeley, University of California San Diego UCSD filed Critical General Hospital Corp
Priority to EP00938260A priority Critical patent/EP1444353A2/en
Publication of WO2000077167A2 publication Critical patent/WO2000077167A2/en
Anticipated expiration legal-status Critical
Publication of WO2000077167A3 publication Critical patent/WO2000077167A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16645—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to herpes simplex virus (HSV) amplicon vectors, and in particular, HSV-1 amplicon vectors, which have been genetically modified and used alone or with consequent genetically modified HSV virus, to target a selected cell type, such as neoplastic cells. The present invention also relates to methods of using such vectors to target a cell, in order to treat a pathologic condition, such as cancer.
PCT/US2000/016050 1999-06-11 2000-06-12 Herpes simplex virus amplicon vector targeting system and method of using same Ceased WO2000077167A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00938260A EP1444353A2 (en) 1999-06-11 2000-06-12 Herpes simplex virus amplicon vector targeting system and method of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13896399P 1999-06-11 1999-06-11
US60/138,963 1999-06-11

Publications (2)

Publication Number Publication Date
WO2000077167A2 WO2000077167A2 (en) 2000-12-21
WO2000077167A3 true WO2000077167A3 (en) 2004-05-06

Family

ID=22484469

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016050 Ceased WO2000077167A2 (en) 1999-06-11 2000-06-12 Herpes simplex virus amplicon vector targeting system and method of using same

Country Status (2)

Country Link
EP (1) EP1444353A2 (en)
WO (1) WO2000077167A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501979A (en) * 1989-02-01 1996-03-26 The General Hospital Corporation Herpes simplex virus type I expression vector
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851826A (en) * 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
AU8605598A (en) * 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501979A (en) * 1989-02-01 1996-03-26 The General Hospital Corporation Herpes simplex virus type I expression vector
US5869331A (en) * 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of EP1444353A4 *
TAL-SINGER ET AL.: "Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules", JOURNAL OF VIROLOGY, vol. 69, no. 7, July 1995 (1995-07-01), pages 4471 - 4483, XP000946705 *
WANG ET AL.: "A hybrid herpesvirus infectious vector based on epstein-barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo", JOURNAL OF VIROLOGY, vol. 70, December 1996 (1996-12-01), pages 8422 - 8430, XP000946704 *

Also Published As

Publication number Publication date
EP1444353A4 (en) 2004-08-11
WO2000077167A2 (en) 2000-12-21
EP1444353A2 (en) 2004-08-11

Similar Documents

Publication Publication Date Title
WO1997021826A3 (en) Complementary adenoviral vector systems and cell lines
MX9800145A (en) Tissue specific viral vectors.
WO1997013866A3 (en) Recombinant herpes virus vectors for expression in neuronal cells
CA2192442A1 (en) Complementary adenoviral vector systems and cell lines
DE69738709D1 (en) HERPES SIMPLEX VIRUS STAEMME
GB2136814B (en) Dna vectors
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
IL110284A0 (en) Viral vectors and their use in gene therapy
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
ZA971159B (en) Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use.
IL181695A0 (en) Methods for cultivating cells and propagating viruses
WO2003068809A8 (en) An herpes simplex virus complex
EP0085548A3 (en) Cloning vectors
WO1995034651A3 (en) Corticotropin-releasing factor2 receptors
AU5318496A (en) Adenovirus vectors for gene therapy
FR2710074B1 (en) GRB3-3 gene, its variants and their uses.
WO2000077167A3 (en) Herpes simplex virus amplicon vector targeting system and method of using same
EP0115173A3 (en) Cloning vectors in streptomyces
WO1998049333A3 (en) Eukaryotic gene expression cassette and uses thereof
EP1144666A3 (en) Replication deficient baculovirus expression system
WO2002064025A3 (en) Inhibition of atf2 activity to treat cancer
WO2002057412A3 (en) Plant promoters, and methods of use
AU3804997A (en) Vectors for inhibiting HIV and tumor growth
AU4306996A (en) Encapsidation cell lines for the transcomplementation of defective retroviral vectors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000938260

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWP Wipo information: published in national office

Ref document number: 2000938260

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000938260

Country of ref document: EP